Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and Bausch Health Companies Inc.'s Expenses

Comparing cost trends of Vertex and Bausch over a decade.

__timestampBausch Health Companies Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014225460000060987000
Thursday, January 1, 20152645000000125542000
Friday, January 1, 20162611000000210460000
Sunday, January 1, 20172548000000275119000
Monday, January 1, 20182351000000409539000
Tuesday, January 1, 20192350000000547758000
Wednesday, January 1, 20202249000000736300000
Friday, January 1, 20212394000000904200000
Saturday, January 1, 202223640000001080300000
Sunday, January 1, 202325590000001262200000
Monday, January 1, 20241530500000
Loading chart...

Unlocking the unknown

Cost Insights: Vertex Pharmaceuticals vs. Bausch Health

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. Over the past decade, Bausch Health Companies Inc. and Vertex Pharmaceuticals Incorporated have showcased contrasting expense trends. From 2014 to 2023, Bausch Health's cost of revenue remained relatively stable, averaging around $2.4 billion annually, with a slight increase of approximately 13% by 2023. In contrast, Vertex Pharmaceuticals experienced a dramatic rise, with costs surging over 1,900% from $61 million in 2014 to $1.26 billion in 2023. This stark difference highlights Vertex's aggressive growth strategy and increased production capabilities. As the pharmaceutical landscape continues to shift, these insights provide a window into the financial strategies of two industry giants, offering valuable lessons for emerging companies and investors alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025